Advertisement
J. Lipid Res.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1194/jlr.D600044-JLR200 on June 4, 2007

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
D600044-JLR200v1
48/9/2086    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Al-Shayji, I. A. R.
Right arrow Articles by Caslake, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Al-Shayji, I. A. R.
Right arrow Articles by Caslake, M. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Journal of Lipid Research, Vol. 48, 2086-2095, September 2007
Copyright © 2007 by American Society for Biochemistry and Molecular Biology

Methods

Development of a novel method to determine very low density lipoprotein kinetics

Iqbal A. R. Al-Shayji*,{dagger}, Jason M. R. Gill1,{dagger}, Josephine Cooney*, Samira Siddiqui*,§ and Muriel J. Caslake*

* Department of Vascular Biochemistry, University of Glasgow, Glasgow, United Kingdom
{dagger} Institute of Diet, Exercise, and Lifestyle, Institute of Biomedical and Life Sciences, University of Glasgow, Glasgow, United Kingdom
§ Renal Unit, Glasgow Royal Infirmary, Glasgow, United Kingdom

Published, JLR Papers in Press, June 4, 2007.

1 To whom correspondence should be addressed. e-mail: j.gill{at}bio.gla.ac.uk


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Isotopic tracer methods of determining triglyceride-rich lipoprotein (TRL) kinetics are costly, time-consuming, and labor-intensive. This study aimed to develop a simpler and cost-effective method of obtaining TRL kinetic data, based on the fact that chylomicrons compete with large VLDL (VLDL1; Sf = 60–400) for the same catalytic pathway. Ten healthy subjects [seven men; fasting triglyceride (TG), 44.3–407.6 mg/dl; body mass index, 21–35 kg/m2] were given an intravenous infusion of a chylomicron-like TG emulsion (Intralipid; 0.1 g/kg bolus followed by 0.1 g/kg/h infusion) for 75–120 min to prevent the clearance of VLDL1 by lipoprotein lipase. Multiple blood samples were taken during and after infusion for separation of Intralipid, VLDL1, and VLDL2 by ultracentrifugation. VLDL1-apolipoprotein B (apoB) and TG production rates were calculated from their linear increases in the VLDL1 fraction during the infusion. Intralipid-TG clearance rate was determined from its exponential decay after infusion. The production rates of VLDL1-apoB and VLDL1-TG were (mean ± SEM) 25.4 ± 3.9 and 1,076.7 ± 224.7 mg/h, respectively, and the Intralipid-TG clearance rate was 66.9 ± 11.7 pools/day. Kinetic data obtained from this method agree with values obtained from stable isotope methods and show the expected relationships with indices of body fatness and insulin resistance (all P < 0.05). The protocol is relatively quick, inexpensive, and transferable to nonspecialist laboratories.

Supplementary key words Intralipid • triglyceride • apolipoprotein B • production • clearance

Abbreviations: apoB, apolipoprotein B; BMI, body mass index; FCR, fractional catabolic rate; FSR, fractional synthetic rate; HOMAIR, homeostasis model assessment insulin resistance; Sf, Svedberg flotation rate; TG, triglyceride; TRL, triglyceride-rich lipoprotein


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
A large body of evidence suggests that increased circulating concentrations of triglyceride-rich lipoproteins (TRLs) increase the risk of atherosclerosis (1, 2). This is particularly evident in the postprandial state (3, 4). However, the measurement of a high TRL concentration provides no information regarding the mechanisms responsible for this increase (i.e., increased rate of synthesis and/or reduced rate of catabolism). As it is important to understand the mechanisms responsible for increased TRL concentrations in different metabolic states, both to advance basic scientific understanding and to help guide therapeutic treatments, studies investigating the kinetics of TRL can yield useful data. Such an approach, for example, has revealed that the dyslipidemia associated with insulin resistance and type 2 diabetes is largely attributable to an overproduction of hepatically derived large VLDL [VLDL1; Svedberg flotation rate (Sf) = 60–400] (5, 6). These studies typically use precursors labeled with stable or radioactive isotope tracers to measure the synthesis of lipids and apolipoproteins directly (7–10). Although these techniques yield detailed kinetic data, they are costly, time-consuming, and labor-intensive and require the use of specialized equipment and techniques in research laboratories.

The aim of this study, therefore, was to develop a relatively straightforward method of obtaining TRL kinetic data. The method relies on the fact that chylomicrons compete with VLDL1 particles for the same catalytic pathway [i.e., hydrolysis of their triglyceride (TG) content by the action of LPL]. Previous studies (11, 12) have shown that VLDL1 accumulates in plasma after fat ingestion or intravenous infusion of a lipid emulsion (e.g., Intralipid) as a result of the presence of the newly secreted chylomicrons or chylomicron-like particles, which are the preferred substrate for LPL because of their larger size and TG content (13). Indeed, using stable isotope methods, Björkegren et al. (12) demonstrated that infusion of Intralipid prevents >90% of VLDL1 catabolism. Therefore, we hypothesized that it would be possible to calculate the production rates of VLDL1-TG and VLDL1-apolipoprotein B (apoB) from the rate of their accumulation during an infusion of Intralipid. The former would be a measure of lipid production, and the latter would represent the rate of VLDL1 particle production, as there is one apoB molecule per VLDL1 particle. Furthermore, using this approach, it is possible to calculate the rate of Intralipid-TG clearance (a surrogate measure of chylomicron-TG clearance) from either the steady-state Intralipid-TG concentration during infusion (14) or the exponential decay in Intralipid-TG concentration after infusion (15). Here, we report the development and validation of this "Intralipid method" to determine TRL kinetics.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Subjects
Ten nonsmoking healthy subjects (seven males and three females) were included in this study after giving written informed consent. All subjects had normal thyroid, liver, and renal function, and none had acute illness, a history of known cardiovascular disease and hypertension, or were under medication known to influence carbohydrate or lipid metabolism. The subjects' characteristics are shown in Table 1 . Subjects were requested not to exercise for 3 days before their tests, as this is known to affect TRL metabolism (16). In addition, they were asked to weigh and record their dietary intake for 2 days before the Intralipid test, and this diet was replicated in those subjects who underwent a second Intralipid test. The study protocol was approved by the Research Ethics Committee of the North Glasgow University Hospitals National Health Service Trust.


View this table:
[in this window]
[in a new window]

  		TABLE 1. Subject physical and metabolic characteristics (n = 10)

 
Intravenous Intralipid test
Each subject reported to the Clinical Investigation Suite in the Department of Vascular Biochemistry at Glasgow Royal Infirmary after an overnight fast of 12 h. Transportation to the hospital was provided for the subjects, when needed, to ensure that they arrived in a rested state. A cannula was introduced into an antecubital vein in both arms, one for administration of Intralipid (purified soybean oil emulsion; Fresenius Kabi, Ltd., Warrington, UK) and the other for blood sampling. The cannulae were kept patent by flushing with nonheparinized saline solution (0.9% NaCl). Ten minutes after cannulation, a first baseline blood sample was obtained. A second baseline blood sample was obtained 10 min later.

The intravenous Intralipid test used was a modification of that described by Björkegren et al. (12). A bolus dose of 20% Intralipid (0.1 g/kg body mass) was injected within 1 min. This was followed immediately by a constant continuous infusion of 10% Intralipid (0.1 g/kg/h). This dose was chosen as Björkegren et al. (12) reported that the rate of increase of VLDL1-apoB during Intralipid infusion was no greater for a 0.2 g/kg/h infusion dose compared with 0.1 g/kg/h, suggesting that the lower dose was sufficient to saturate LPL and prevent measurable VLDL1 catabolism. However, we also performed experiments with the 0.2 g/kg/h dose ourselves to confirm that this was the case in our hands (see below). Initially, the infusion period was 120 min; however, during development of the technique, this was subsequently decreased to 75 min after it became clear that a 75 min infusion was long enough to induce a sufficient measurable increase in VLDL1-TG and VLDL1-apoB.

Blood samples were obtained at 15 min intervals during the infusion. Further blood samples were drawn at 2.5, 5, 10, 15, 20, 30, 45, 60, and 75 min after infusion. Initially, the postinfusion period was 3.25 h. However, this was subsequently decreased to 75 min when it became clear that this was sufficient to calculate the Intralipid-TG clearance rate using the exponential decay. All samples were obtained directly into potassium EDTA tubes (BD Vacutainer Systems, Plymouth, UK) and placed immediately in ice before centrifuging for 15 min at 3,000 rpm and 4°C.

Aliquots of plasma were frozen immediately at –70°C for subsequent analysis of insulin, NEFA, glucose, TG, total cholesterol, and HDL cholesterol. The remaining plasma was stored overnight at 4°C before separation of Intralipid and lipoproteins.

Increasing the Intralipid infusion rate
Five subjects [two females and three males; age, 23–47 years (range); body mass index (BMI), 20.8–28.7 kg/m2; fasting TG, 53.2–230.4 mg/dl] underwent a second test using a higher infusion dose (0.2 g/kg/h) of 10% Intralipid with the same 0.1 g/kg bolus dose. This was done to determine whether the Intralipid infusion dose of 0.1 g/kg/h was sufficient to completely prevent measurable lipolysis of VLDL1 by LPL and, therefore, enable determination of VLDL1-TG and VLDL1-apoB production rates from their increases in concentration. If the infusion rate of 0.1 g/kg/h was sufficient to saturate LPL and block lipolysis of VLDL1, the 0.2 g/kg/h dose would not result in higher calculated production rates of VLDL1-TG or VLDL1-apoB compared with the 0.1 g/kg/h dose. The order of testing was randomized. Other than the higher infusion dose, all conditions of the tests were the same.

Intralipid (Sf > 400) separation from whole plasma
Two milliliters of plasma were overlaid with 4 ml of 1.006 g/ml density solution in ultraclear centrifuge tubes and spun at 10,000 rpm and 4°C for 30 min (17) using a Beckman L8-M Ultracentrifuge and a Beckman 50.4 rotor (Beckman Instruments, Inc.). Intralipid (d <1.006 g/ml) was removed in the top 2 ml (IL-1) for subsequent measurements of TG using commercially available enzymatic colorimetric kits (Roche Diagnostics GmbH, Mannheim, Germany). TG concentration was also measured in the middle 1.5 ml fraction (IL-2) to verify complete separation of Intralipid. The final Intralipid-TG concentration was calculated as the addition of these two fractions [IL-1 + (IL-2 x 1.5/2)]. In addition, glycerol was measured in these IL-1 and IL-2 fractions using commercially available kits (Randox Laboratories, Ltd.) to determine the amount of free glycerol. The final 0.5 ml of the density solution was discarded, and the remaining 2 ml of Intralipid-free plasma was used for the separation of VLDL1 and VLDL2. The coefficient of variation (CV) for the Intralipid-TG separation was 6.9%.

VLDL1 and VLDL2 separation
VLDL1 (Sf = 60–400) and VLDL2 (Sf = 20–60) were isolated from plasma using a modification of the cumulative ultracentrifugation density gradient technique described by Lindgren, Jensen, and Hatch (18). TG concentrations were then measured in the VLDL1 and VLDL2 fractions at all time points using commercially available kits as described previously. ApoB concentrations were also measured directly by immunoturbidimetry using commercially available kits (WAKO Apolipoprotein B-HA; Wako Chemicals GmbH). The CVs for the separation of VLDL1-TG and VLDL1-apoB were 5.0% and 3.4%, respectively, and those for VLDL2-TG and VLDL2-apoB were 5.8% and 1.4%, respectively.

Fasting plasma analysis
Plasma glucose, total cholesterol, and HDL cholesterol concentrations in the fasted state and TG and NEFA concentrations at all time points were analyzed using commercially available enzymatic colorimetric kits [glucose hexokinase (Randox Laboratories, Ltd.); total cholesterol and HDL cholesterol (Roche Diagnostics GmbH); free fatty acid (Wako Chemicals USA, Inc.)]. Fasting insulin was analyzed using commercially available ELISA kits (Mercodia Insulin ELISA).

Correction for glycerol
Enzymatic kits for TG analysis measure the glycerol that is hydrolyzed from TG by LPL. As Intralipid contains free glycerol as an excipient, it has been reported that it overestimates the true TG concentrations of Intralipid (19). Therefore, all Intralipid-TG measurements were corrected for free glycerol and are reported as "true" TG concentrations [true TG concentration (mg/dl) = {measured TG (mmol/l) – glycerol (mmol/l)} x 88.6]. Glycerol concentrations were also measured in five subjects in the VLDL1 fraction during infusion and were found to be negligible (influencing VLDL1-TG concentrations by <1%).

Kinetic data calculations
The clearance rates of Intralipid-TG and production rates of VLDL1-TG and VLDL1-apoB were calculated as described below using examples from individual subjects.

Calculating VLDL1-TG and VLDL1-apoB production rates The production rates (mg/h) of VLDL1-TG and VLDL1-apoB were calculated from the gradient of the linear increase in their concentrations (mg/dl) over time (min) multiplied by plasma volume [4% of body mass (20)] in deciliters and then by 60 min.

Figure 1A represents the linear increase in TG (mg/dl) in the VLDL1 fraction of subject 3 (female, 55 years, 84.5 kg), with R2 (goodness-of-fit) value of 0.97 and a gradient of 1.0589. Assuming this subject's plasma volume is 3.38 liters (33.8 dl), the VLDL1-TG production rate would be (1.0589 x 33.8 x 60) 2,147.4 mg/h (609.9 mg/kg/day). Similarly, from Fig. 1B, the VLDL1-apoB production rate of the same subject was 50.9 mg/h (14.5 mg/kg/day).


Figure 1
View larger version (8K):
[in this window]
[in a new window]

  		Fig. 1. Changes in VLDL1-triglyceride (TG) (A) and VLDL1-apolipoprotein B (apoB) (B) concentrations (mg/dl) in a female subject (55 years, 84.5 kg) during infusion of 10% Intralipid (0.1 g/kg/h). An initial bolus dose of 20% Intralipid (0.1 g/kg body mass) was given at 0 min. Equations of the line are as follows: for A, y = 1.0589x + 61.191 (R2 = 0.97); for B, y = 0.0251x + 1.9185 (R2 = 0.97).

 
Calculating VLDL1-TG and VLDL1-apoB fractional synthetic and catabolic rates The fractional synthetic rate (FSR) is defined as the rate of incorporation of a precursor into a product per unit of product mass (21), which can be calculated as:

Formula 1(Eq. 1)
In this method, the FSR of VLDL1-TG and VLDL1-apoB (pools/day) can be calculated from the gradient of the linear increase in their concentrations (mg/dl) over time (min) divided by fasting concentrations (mg/dl) and then multiplied by 60 min and 24 h. However, because the system is in a steady state in fasting conditions, in which the synthesis of VLDL1 equals its clearance, FSR will also be equivalent to the fractional catabolic rate (FCR) in the fasted state (21).

From Table 2 , subject 3 had VLDL1-TG and VLDL1-apoB fasting concentrations of 49.4 and 1.8 mg/dl, respectively. According to the equation of the line in Fig. 1A, the subject's VLDL1-TG FSR and FCR were (1.0589 ÷ 49.4 x 60 x 24) 30.9 pools/day. Similarly, from Fig. 1B, the VLDL1-apoB FSR and FCR were 19.8 pools/day.


View this table:
[in this window]
[in a new window]

  		TABLE 2. Fasting concentrations and individual lipoprotein kinetic parameters calculated using the Intralipid method (0.1 g/kg/h infusion dose) in the 10 subjects studied

 
Calculating Intralipid-TG clearance rate Assuming that all TG clearance is Intralipid-TG clearance, it is possible to determine Intralipid-TG clearance rate in two ways:

The Steady-State Method. The clearance rate of Intralipid-TG can be calculated from the steady-state concentration during infusion using the following equation (14):

Formula 2(Eq. 2)
In this method, we defined that a steady state was achieved when the final three values of the Intralipid-TG concentrations differed by <13.8% (i.e., two times the CV for the separation of the Intralipid fraction and measurement of the TG; this represents the 95% confidence interval for the measured value). To calculate the clearance rate in pools per day, the values were divided by plasma volume (4% of body mass) and then multiplied by 60 min and 24 h.

The Exponential Method. After stopping the intravenous infusion, Intralipid-TG declines exponentially according to first-order kinetics as described by Rössner (15). The Intralipid-TG clearance rate can be calculated from the Intralipid-TG concentrations (mg/dl) after infusion over time (min) curve plotted on a semilog scale. The equation of the fitted line is:

Formula 3(Eq. 3)
where k is the proportionality constant, t is the time, and b is the exponential decay constant, which in turn is defined as:

Formula 4(Eq. 4)
Hence,

Formula 5(Eq. 5)

Intralipid recovery
To assess the recovery of plasma-Intralipid in the Intralipid fraction (Sf > 400), EDTA plasma was spiked with Intralipid to produce an Intralipid-TG concentration in plasma of ~133 and ~354 mg/dl. These reflect approximate Intralipid-TG concentrations at the 0.1 and 0.2 g/kg/h infusion doses. For each Intralipid concentration, samples of spiked plasma were divided into 10 aliquots, and the Intralipid fractions were separated as described above. TG and glycerol concentrations were measured in plasma before and after addition of the Intralipid (to calculate the actual Intralipid-TG concentration) as well as in the separated Intralipid fractions. The Intralipid recovery was calculated as follows:

Formula 6(Eq. 6)
where actual Intralipid-TG = total TG (plasma with Intralipid) – TG (Intralipid-free plasma).

Statistical analyses
Statistical analyses were performed using MINITAB for Windows (version 13.1; MINITAB, Inc., State College, PA) and STATISTICA (release 6.0; StatSoft, Inc.). Normality was checked for all of the data using the Anderson-Darling test. When data did not approximate a normal distribution, these were log-transformed, specifically TG, glucose, homeostasis model assessment insulin resistance (HOMAIR), production rates of VLDL1-TG (expressed in both mg/h and mg/kg/day) and VLDL1-apoB (expressed in mg/h), Intralipid-TG clearance rate, and VLDL1-apoB FSR required transformation. Time trends were tested using one-way ANOVA with repeated measures. Paired t-tests were used to compare between the Intralipid-TG clearance rates calculated from the steady state and the exponential decay and between the kinetic data obtained from the low and high Intralipid doses. The HOMA was used as a validated surrogate measure of insulin resistance (22). Relationships between HOMAIR, NEFA, BMI, waist circumference, and kinetic parameters were assessed using Pearson product-moment correlations. Significance was accepted at the P < 0.05 level. Data are presented as means ± SEM unless stated otherwise.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Plasma-, Intralipid-, VLDL1-, and VLDL2-TG concentrations during and after infusion
Figure 2A shows the mean plasma-, Intralipid-, VLDL1-, and VLDL2-TG responses in 10 subjects during 75 min Intralipid infusion (0.1 g/h/kg body mass). Plasma-TG concentrations were increased to approximately two to three times the fasting value during the infusion. Similarly, mean Intralipid-TG concentrations increased in response to the bolus dose (P < 0.001). VLDL1-TG concentrations increased linearly during the infusion (P < 0.001), but VLDL2-TG did not change significantly during the course of the infusion (P = 0.14).


Figure 2
View larger version (11K):
[in this window]
[in a new window]

  		Fig. 2. Plasma-, Intralipid-, VLDL1-, and VLDL2-TG concentrations (mg/dl) during infusion of 0.1 g/kg/h 10% Intralipid (A) and for 75 min after infusion (B). An initial bolus dose of 20% Intralipid (0.1 g/kg body mass) was given at 0 min. Values are means ± SEM; n = 10.

 
After stopping the infusion, the plasma- and Intralipid-TG concentrations decreased exponentially (both P < 0.001; Fig. 2B). VLDL1-TG continued to increase for ~20 min before plateauing and subsequently decreasing. In subjects in whom the postinfusion period was extended, VLDL1-TG returned to baseline concentrations within 105–135 min (data not shown). The mean VLDL2-TG concentrations remained unchanged for the 75 min postinfusion observation period.

VLDL1-apoB and VLDL2-apoB concentrations during infusion
The mean apoB concentration in the VLDL1 (Sf = 60–400) fraction increased steadily from fasting levels throughout the infusion and was significantly higher than baseline within 15 min (P < 0.001). On the other hand, mean VLDL2-apoB concentrations declined significantly (P < 0.001) during 75 min of infusion. Total (VLDL1 + VLDL2) VLDL-apoB concentrations increased slightly but significantly (P < 0.05) during infusion (Fig. 3 ). There was no significant change in the VLDL1-TG/apoB or VLDL2-TG/apoB ratio (expressed in mmol/mmol) over the 75 min of infusion (P = 0.21 and P = 0.16, respectively).


Figure 3
View larger version (10K):
[in this window]
[in a new window]

  		Fig. 3. VLDL1-apoB, VLDL2-apoB, and total VLDL-apoB concentrations (mg/dl) during infusion of 10% Intralipid (0.1 g/kg/h). An initial bolus dose of 20% Intralipid (0.1 g/kg body mass) was given at 0 min. Values are means ± SEM; n = 10.

 
Kinetic data
Table 2 shows the production rates and FSR of VLDL1-TG and VLDL1-apoB as well as the clearance rates of Intralipid-TG calculated for each subject (n = 10) as described previously. Fasting VLDL1-TG and VLDL1-apoB and VLDL2-apoB concentrations are also presented.

VLDL1-TG and VLDL1-apoB production rates The mean ± SEM (range) production rates for VLDL1-TG and VLDL1-apoB were 1,076.7 ± 224.7 (446.0–2,563.2) mg/h and 25.4 ± 3.9 (12.0–50.9) mg/h, respectively. These corresponded to 333.6 ± 49.1 (198.5–609.9) mg/kg/day and 8.1 ± 0.9 (4.4–14.5) mg/kg/day, respectively.

VLDL1-TG and VLDL1-apoB FSRs and FCRs The mean ± SEM (range) VLDL1-TG and VLDL1-apoB FSRs, which are equal to the VLDL1-TG and VLDL1-apoB FCRs in the fasted state (21), were 30.2 ± 5.7 (6.5–57.8) pools/day and 21.1 ± 5.1 (2.2–56.2) pools/day, respectively.

Intralipid-TG clearance rate The Intralipid-TG clearance rates calculated for individual subjects by the two methods described above (i.e., steady state and exponential) are shown in Table 2. Eight of the 10 subjects reached the defined steady state during infusion. The mean ± SEM Intralipid-TG clearance rates in these eight subjects did not differ significantly between the two calculation methods (52.4 ± 8.6 pools/day for steady state versus 55.3 ± 9.2 pools/day for exponential; P = 0.45), and the values obtained were strongly correlated (r = 0.96, P < 0.001). However, because not all subjects reached a steady state, the Intralipid-TG clearance rates mentioned hereafter will refer to those calculated using the exponential method.

Effect of increasing the Intralipid infusion rate
For the five subjects who underwent Intralipid infusion at the low (0.1 g/kg/h) and high (0.2 g/kg/h) doses, there were no significant differences in the mean VLDL1-apoB production rates (low dose, 23.8 ± 2.8 vs. high dose, 22.0 ± 1.9 mg/h; P = 0.21) or VLDL1-TG production rates (low dose, 813.8 ± 127.0 vs. high dose, 960.9 ± 136.8 mg/h; P = 0.10) between the low and high doses, although there was a tendency for the VLDL1-TG production rate to be higher at the high Intralipid dose. However, we had observed that separation of the large amount of Intralipid from plasma at the higher (0.2 g/kg/h) dose was technically quite difficult and suspected that the VLDL1 fraction in some samples may have become slightly contaminated with Intralipid at this dose. This suggestion is supported by the substantially lower recovery of Intralipid in the Intralipid fraction at high Intralipid concentrations (see below). Calculated FSRs for VLDL1-TG (low dose, 30.1 ± 8.8 vs. high dose, 30.4 ± 8.1 pools/day; P = 0.94) and VLDL1-apoB (low dose, 28.5 ± 8.7 vs. high dose, 33.4 ± 14.6 pools/day; P = 0.64) did not differ between the two doses, and FSRs for VLDL1-TG (r = 0.88, P = 0.05) and VLDL1-apoB (r = 0.95, P = 0.01) between the two doses correlated highly with each other and, when plotted, followed the line of equality (Fig. 4 ).


Figure 4
View larger version (10K):
[in this window]
[in a new window]

  		Fig. 4. Scatterplots (with the line of equality) illustrating the agreement between VLDL1-TG fractional synthetic rate (FSR; pools/day) (A) and natural logarithm (Ln) VLDL1-apoB FSR between the low (0.1 g/kg/h) and high (0.2 g/kg/h) doses (B). FSR is equivalent to fractional catabolic rate in the fasted state. n = 5; r and P values are for Pearson product-moment correlations between variables. VLDL1-apoB FSR is expressed in pools/day before log transformation.

 
Intralipid recovery
Recovery of the Intralipid-TG in the Intralipid (Sf > 400) fraction was 95 ± 7% (mean ± SD) for the ~133 mg/dl Intralipid-TG concentration and 71 ± 4% for the ~354 mg/dl Intralipid-TG concentration.

Interrelationships between VLDL1-TG and VLDL1-apoB production and TG clearance
Intralipid-TG clearance rate and VLDL1-TG and VLDL1-apoB production rates (expressed in mg/h) were significantly interrelated, with the expected negative correlation between Intralipid-TG clearance and VLDL1-TG (r = –0.67, P = 0.04) and VLDL1-apoB (r = –0.69, P = 0.03) production rates and a positive correlation between VLDL1-TG and VLDL1-apoB production rates (r = 0.85, P = 0.002). There was also a very strong relationship between VLDL1-TG FSR (which equals the VLDL1-TG FCR in the fasted state) and Intralipid-TG clearance rate (r = 0.90, P < 0.005). The positive correlation between VLDL1-TG and VLDL1-apoB production rates remained significant between production rates when values were expressed in mg/kg/day (r = 0.73, P = 0.02). However, the relationships between VLDL1-TG production rate expressed in mg/kg/day and Intralipid-TG clearance (r = –0.46, P = 0.18) and between VLDL1-apoB production rate expressed in mg/kg/day and Intralipid-TG clearance (r = –0.28, P = 0.44) were not statistically significant.

Relationships between kinetic variables and subject characteristics
Figure 5 shows the relationships between the measured kinetic variables and subject characteristics, with VLDL1-TG and VLDL1-apoB production rates expressed in mg/h. VLDL1-TG and VLDL1-apoB production rates correlated strongly and significantly with waist circumference and fasting TG concentration. VLDL1-TG production rate also correlated significantly with HOMAIR. Similarly, Intralipid-TG clearance rate was significantly and inversely correlated with waist circumference, fasting TG concentrations, and HOMAIR. In addition, BMI correlated significantly and positively with VLDL1-TG (r = 0.83, P = 0.003) and VLDL1-apoB (r = 0.81, P = 0.004) production rates and inversely with Intralipid-TG clearance rate (r = –0.60, P = 0.07). Fasting NEFA concentrations were not significantly correlated with any of the kinetic variables. The relationships between VLDL1-TG and VLDL1-apoB production rates expressed in mg/kg/day with BMI, waist circumference, fasting TG concentration, and HOMAIR are shown in Table 3 . The correlations between VLDL1-TG production and all of these variables remained strong and statistically significant; however, the correlations between VLDL1-apoB production rate and waist circumference and fasting TG were not statistically significant when the production rates were normalized for body mass.


Figure 5
View larger version (22K):
[in this window]
[in a new window]

  		Fig. 5. Scatterplots (with linear regression lines of best fit) illustrating the relationships between the kinetic variables [VLDL1-TG production rate (left), VLDL1-apoB production rate (middle), and Intralipid-TG clearance rate (right)] and subject characteristics: waist circumference (top), fasting TG concentrations (middle), and homeostasis model assessment insulin resistance (HOMAIR) (bottom). n = 10; r and P values are for Pearson product-moment correlations between variables. VLDL1-apoB and VLDL1-TG production rates are expressed in mg/h, and Intralipid clearance rate is expressed in pools/day before log transformation.

 

View this table:
[in this window]
[in a new window]

  		TABLE 3. Correlations between VLDL1-apoB and VLDL1-TG production rates (expressed in mg/kg/day) and subject characteristics

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
In this study, we have developed a relatively straightforward method of determining TRL kinetics. The method relies on the fact that chylomicrons or chylomicron-like particles, such as Intralipid, compete with hepatically derived large VLDL1 particles for clearance by a common saturable pathway [i.e., hydrolysis of their TG content by LPL (11, 12)] and that chylomicrons or chylomicron-like particles are the preferred substrate for LPL (13). Thus, the presence of a sufficient concentration of chylomicrons or chylomicron-like particles in the circulation will almost entirely prevent the clearance of VLDL1 by LPL (12); therefore, the rates of VLDL1-TG and VLDL1-apoB production can be calculated from their rates of increase in concentration. This work builds on the findings of Björkegren et al. (12), who, in studies designed to evaluate the effects of Intralipid infusion on VLDL1 (Sf = 60–400) and VLDL2 (Sf = 20–60) kinetics, found that individual rates of VLDL1-apoB production calculated from the rate of increase of VLDL1-apoB during infusion were virtually identical to those calculated from the "gold-standard" stable isotope method (see below). The Intralipid method described here enables the determination of the rates of VLDL1-TG (i.e., VLDL1 lipid) and VLDL1-apoB (i.e., VLDL1 particle) production as well as the clearance rates of chylomicron-like particles.

The Intralipid method specifically measures the production rate of large VLDL1 rather than total VLDL (i.e., Sf = 20–400). VLDL is a metabolically heterogeneous class of lipoproteins, and it is the larger VLDL1 subclass that competes with chylomicrons/chylomicron-like particles for LPL-mediated clearance and would have its clearance blocked by the presence of Intralipid (12). In contrast, catabolism of the smaller VLDL2 subclass would not be blocked completely by Intralipid, as its clearance can occur via the action of hepatic lipase as well as LPL (23). Indeed, as one source of VLDL2 is from the catabolism of VLDL1 (the other being direct hepatic production) and this process was blocked by Intralipid infusion, mean VLDL2-apoB concentrations decreased slightly during the infusion, although individual responses were more heterogeneous than those observed with VLDL1-apoB, a finding also reported by Björkegren et al. (12). This heterogeneity in individual VLDL2-apoB responses meant that it was not possible to perform any kinetic analyses using the VLDL2 data.

To validate the calculation of VLDL1-apoB and VLDL1-TG production rates using the Intralipid method, it was necessary to consider a number of issues. The first was to determine whether infusing a higher Intralipid dose would influence the calculated VLDL1-apoB and VLDL1-TG production rates. This was necessary to establish whether the proposed Intralipid infusion dose of 0.1 g/kg/h was sufficient to saturate LPL and block the clearance of VLDL1: if the 0.1 g/kg/h dose was sufficient, infusing a higher Intralipid dose should not affect the calculated production rates. In agreement with the findings of Björkegren et al. (12), we found that the calculated VLDL1-apoB production rate was not changed when a higher (0.2 g/kg/h) Intralipid infusion dose was used. Similarly, FSRs, which correspond to the FCRs in the fasted state, for VLDL1-apoB and VLDL1-TG did not differ between the two doses (Fig. 4). We did observe a tendency for the calculated VLDL1-TG production rate to be higher with the 0.2 g/kg/h dose, although this was not statistically significant. However, we feel that the slightly higher apparent VLDL1-TG production rate at the high dose was a methodological, rather than a physiological, issue caused by the difficulty in separating Intralipid at the high dose, leading to the potential contamination of VLDL1 fraction with Intralipid. This is supported by the fact that Intralipid recoveries at high Intralipid doses were relatively low (71% at an Intralipid concentration of 354 mg/dl). This contrasts with the nearly complete recovery of Intralipid at lower Intralipid doses (95% at an Intralipid concentration of 133 mg/dl). This, of course, would not influence the VLDL1-apoB production rate calculations, as Intralipid particles do not contain apoB.

A further issue to consider is whether, after lipolysis by LPL, Intralipid "remnant" particles may have appeared in the VLDL1 fraction, thereby increasing the measured VLDL1-TG concentration and the apparent VLDL1-TG production rate. However, we do not believe that this would have had a substantial effect on calculated VLDL1-TG production rates, for a number of reasons. First, evidence from the literature suggests that for large TG-rich particles, particularly chylomicron-like particles, lipolysis and particle removal from the plasma are likely to occur simultaneously, rather than by sequential mechanisms (24, 25), with the majority of particles removed from the plasma before conversion to smaller VLDL-sized remnant particles (26). Second, as Intralipid contains TG but not apoB, the appearance of Intralipid remnants in the VLDL1 fraction would lead to a disproportionate increase in VLDL1-TG compared with VLDL1-apoB, leading to an increase in the VLDL1-TG/apoB ratio. We did not observe a significant increase in this ratio during the infusion (P = 0.21). Third, if the increase in VLDL1-TG was influenced by the appearance of Intralipid remnant particles, then a positive correlation between Intralipid clearance and VLDL1-TG production would be evident (i.e., increased Intralipid clearance would lead to increased VLDL1-TG production). Instead, a negative relationship between Intralipid clearance and VLDL1-TG production (expressed in mg/h) was observed (i.e., subjects with slow Intralipid clearance also had high VLDL1-TG production) (r = –0.67, P = 0.04). Furthermore, the relationship between VLDL1-apoB production, which would be unaffected by the presence of Intralipid remnant particles, and VLDL1-TG production was very strong, with 71% of the variance in the VLDL1-TG production rate explained by the VLDL1-apoB production rate (r = 0.85, P = 0.002).

Furthermore, it is important to ascertain whether the results obtained are comparable with data obtained using the gold standard stable isotope tracer method. An internal validation of this method was previously undertaken by Björkegren and colleagues (12) in three subjects. They reported VLDL1-apoB production rates of 20.0, 25.6, and 7.2 mg/h calculated from the Intralipid infusion method, with corresponding rates calculated from a stable isotope method of 23.8, 21.6, and 8.0 mg/h, respectively, indicating that data obtained from the two methods were comparable. In addition, from Table 4 , it is clear that the values for VLDL1-apoB production in the present study are of the same order as those obtained from a number of studies that determined VLDL1-apoB production using staple isotope techniques. Determination of VLDL1-TG production rates using stable isotope tracer methods is technically more difficult than determination of VLDL1-apoB production, and the authors are only aware of one group of workers who have evaluated this (7, 27). The values obtained for VLDL1-TG production in our study are of the same order as those published by Adiels et al. (7, 27).


View this table:
[in this window]
[in a new window]

  		TABLE 4. Comparison of values for VLDL1-TG and VLDL1-apoB production rates (ranges) calculated in this study (Intralipid method) and in previously published studies using the stable isotope method

 
This Intralipid method enabled the Intralipid-TG clearance rate to be calculated in two different ways: from the steady state concentration of Intralipid-TG during the infusion, which we defined as the mean of the final three values if these differed by <13.8% (i.e., two times the CV for the separation of the Intralipid fraction and measurement of the TG), and from the exponential decrease in Intralipid-TG after infusion (15). In subjects in whom a steady-state Intralipid-TG concentration was achieved, the Intralipid-TG clearance rates calculated from the steady-state concentration and from the postinfusion exponential decrease agreed closely (Table 2). However, not all subjects achieved a steady-state Intralipid-TG concentration in 75 min of infusion, and it is not possible to determine whether a steady state was achieved for a given subject until sample analysis was completed. Therefore, in practice, it may be easier to use the postinfusion values to determine Intralipid-TG clearance rates, as this ensures that the Intralipid infusion can be kept as short as necessary to enable the calculation of VLDL1-TG and VLDL1-apoB production rates.

Finally, we sought to determine whether this Intralipid method revealed the physiologically expected differences in TRL kinetics between subjects with differing physical and metabolic profiles. As expected, there were strong positive correlations between fasting TG concentrations and VLDL1-TG production rates, expressed in either absolute terms or normalized according to body mass, and between fasting TG and VLDL1-apoB production, expressed in mg/h, with a strong negative correlation between fasting TG and the Intralipid-TG clearance rates, indicating that those with high TG exhibited a combination of enhanced VLDL1 production and diminished TG clearance. VLDL1-TG FCR in the fasted state (i.e., with no Intralipid present) was ~45% of the Intralipid-TG clearance rate (30.2 ± 5.7 vs. 66.2 ± 11.7 pools/day; Table 2), and there was a very strong correlation between these two variables (r = 0.90, P < 0.0005), indicating that clearance rates for VLDL1 and chylomicron-like particles within an individual are very tightly linked, consistent with the fact that these particles are cleared by the same pathway. The expected positive correlations between indices of body fatness (waist circumference and BMI) and insulin resistance (HOMAIR) and VLDL1-TG and VLDL1-apoB production rates were also observed, in agreement with findings we reported previously using stable isotope tracer methods (8). We also observed significant negative relationships between Intralipid-TG clearance and HOMAIR and waist circumference. Thus, the Intralipid method appears to be sensitive enough to detect physiologically relevant differences in TRL kinetics between individuals across the normal and moderately hypertriglyceridemic range.

In conclusion, we have developed a novel method to determine TRL kinetics. The Intralipid method provides a relatively straightforward and cost-effective way of determining VLDL1-TG and VLDL1-apoB production rates and the clearance rate of chylomicron-like particles that does not require specialized equipment, such as a mass spectrometer. We believe that this method will increase the scope for the study of TRL kinetics, particularly in circumstances in which issues related to funding or equipment availability preclude the use of more traditional isotopic tracer methods.


   ACKNOWLEDGMENTS
 
I.A.R.A. was supported by the Public Authority of Applied Education and Training from the government of Kuwait. The authors thank Mrs. Dorothy Bedford for technical assistance. The authors also thank Prof. Chris Packard for his valuable advice in the design of the study and the interpretation of the data. Finally, the authors thank Dr. Chris Deighan for medical assistance.

Manuscript received November 13, 2007 and in revised form April 4, 2007 and in re-revised form June 1, 2007.


   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
  1. Malloy, M. J., and J. P. Kane. 2001. A risk factor for atherosclerosis: triglyceride-rich lipoproteins. Adv. Intern. Med. 47: 111–136.[Medline]

  2. Tanaka, A., M. Ai, Y. Kobayashi, M. Tamura, K. Shimokado, and F. Numano. 2001. Metabolism of triglyceride-rich lipoproteins and their role in atherosclerosis. Ann. N. Y. Acad. Sci. 947: 207–212.[Medline]

  3. Karpe, F. 1999. Postprandial lipoprotein metabolism and atherosclerosis. J. Intern. Med. 246: 341–355.[CrossRef][Medline]

  4. Schneeman, B. O., L. Kotite, K. M. Todd, and R. J. Havel. 1993. Relationships between the responses of triglyceride-rich lipoproteins in blood plasma containing apolipoproteins B-48 and B-100 to a fat-containing meal in normolipidemic humans. Proc. Natl. Acad. Sci. USA. 90: 2069–2073.[Abstract/Free Full Text]

  5. Watson, K. E., B. N. Horowitz, and G. Matson. 2003. Lipid abnormalities in insulin resistant states. Rev. Cardiovasc. Med. 4: 228–236.[Medline]

  6. Adiels, M., J. Boren, M. J. Caslake, P. Stewart, A. Soro, J. Westerbacka, B. Wennberg, S. O. Olofsson, C. Packard, and M. R. Taskinen. 2005. Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterioscler. Thromb. Vasc. Biol. 25: 1697–1703.[Abstract/Free Full Text]

  7. Adiels, M., C. Packard, M. J. Caslake, P. Stewart, A. Soro, J. Westerbacka, B. Wennberg, S. O. Olofsson, M. R. Taskinen, and J. Boren. 2005. A new combined multicompartmental model for apolipoprotein B-100 and triglyceride metabolism in VLDL subfractions. J. Lipid Res. 46: 58–67.[Abstract/Free Full Text]

  8. Gill, J. M., J. C. Brown, D. Bedford, D. M. Wright, J. Cooney, D. A. Hughes, C. J. Packard, and M. J. Caslake. 2004. Hepatic production of VLDL1 but not VLDL2 is related to insulin resistance in normoglycaemic middle-aged subjects. Atherosclerosis. 176: 49–56.[CrossRef][Medline]

  9. Packard, C. J., T. Demant, J. P. Stewart, D. Bedford, M. J. Caslake, G. Schwertfeger, A. Bedynek, J. Shepherd, and D. Seidel. 2000. Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions. J. Lipid Res. 41: 305–318.[Abstract/Free Full Text]

  10. Packard, C. J. 1995. The role of stable isotopes in the investigation of plasma lipoprotein metabolism. Baillieres Clin. Endocrinol. Metab. 9: 755–772.[CrossRef][Medline]

  11. Karpe, F., and M. Hultin. 1995. Endogenous triglyceride-rich lipoproteins accumulate in rat plasma when competing with a chylomicron-like triglyceride emulsion for a common lipolytic pathway. J. Lipid Res. 36: 1557–1566.[Abstract]

  12. Björkegren, J., C. J. Packard, A. Hamsten, D. Bedford, M. Caslake, L. Foster, J. Shepherd, P. Stewart, and F. Karpe. 1996. Accumulation of large very low density lipoprotein in plasma during intravenous infusion of a chylomicron-like triglyceride emulsion reflects competition for a common lipolytic pathway. J. Lipid Res. 37: 76–86.[Abstract]

  13. Fisher, R. M., S. W. Coppack, S. M. Humphreys, G. F. Gibbons, and K. N. Frayn. 1995. Human triacylglycerol-rich lipoprotein subfractions as substrates for lipoprotein lipase. Clin. Chim. Acta. 236: 7–17.[CrossRef][Medline]

  14. Rang, H. P., M. M. Dale, J. M. Ritter, and P. K. Moore, editors. 2003. Pharmacology. Churchill Livingstone, London.

  15. Rössner, S. 1974. Studies on an intravenous fat tolerance test. Methodological, experimental and clinical experiences with Intralipid. Acta Med. Scand. Suppl. 564: 1–24.[Medline]

  16. Gill, J. M., and A. E. Hardman. 2003. Exercise and postprandial lipid metabolism: an update on potential mechanisms and interactions with high-carbohydrate diets (Review). J. Nutr. Biochem. 14: 122–132.[CrossRef][Medline]

  17. Havel, R. J., H. A. Eder, and J. H. Bragdon. 1955. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 34: 1345–1353.[Medline]

  18. Lindgren, F. T., L. C. Jensen, and F. T. Hatch. 1972. The isolation and quantitative analysis of serum lipoproteins. In Blood Lipids and Lipoproteins: Quantitation, Composition, and Metabolism. G. J. Nelson, editor. John Wiley and Sons, New York. 181–274.

  19. Howdieshell, T. R., N. Bhalla, J. T. DiPiro, T. Kuske, and R. Baisden. 1995. Effects of free glycerol contained in intravenous fat emulsion on plasma triglyceride determination. JPEN J. Parenter. Enteral Nutr. 19: 125–126.[Abstract/Free Full Text]

  20. Packard, C. J., A. Munro, A. R. Lorimer, A. M. Gotto, and J. Shepherd. 1984. Metabolism of apolipoprotein B in large triglyceride-rich very low density lipoproteins of normal and hypertriglyceridemic subjects. J. Clin. Invest. 74: 2178–2192.[Medline]

  21. Foster, D. M., P. H. Barrett, G. Toffolo, W. F. Beltz, and C. Cobelli. 1993. Estimating the fractional synthetic rate of plasma apolipoproteins and lipids from stable isotope data. J. Lipid Res. 34: 2193–2205.[Abstract]

  22. Matthews, D. R., J. P. Hosker, A. S. Rudenski, B. A. Naylor, D. F. Treacher, and R. C. Turner. 1985. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 28: 412–419.[CrossRef][Medline]

  23. Packard, C., and J. Shepherd. 1997. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler. Thromb. Vasc. Biol. 17: 3542–3556.[Abstract/Free Full Text]

  24. Olivecrona, G., and T. Olivecrona. 1998. Clearance of artificial triacylglycerol particles. Curr. Opin. Clin. Nutr. Metab. Care. 1: 143–151.[CrossRef][Medline]

  25. Hultin, M., R. Savonen, and T. Olivecrona. 1996. Chylomicron metabolism in rats: lipolysis, recirculation of triglyceride-derived fatty acids in plasma FFA, and fate of core lipids as analyzed by compartmental modelling. J. Lipid Res. 37: 1022–1036.[Abstract]

  26. Karpe, F., T. Olivecrona, A. Hamsten, and M. Hultin. 1997. Chylomicron/chylomicron remnant turnover in humans: evidence for margination of chylomicrons and poor conversion of larger to smaller chylomicron remnants. J. Lipid Res. 38: 949–961.[Abstract]

  27. Adiels, M., M. R. Taskinen, C. Packard, M. J. Caslake, A. Soro-Paavonen, J. Westerbacka, S. Vehkavaara, A. Hakkinen, S. O. Olofsson, H. Yki-Jarvinen, et al. 2006. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia. 49: 755–765.[CrossRef][Medline]

  28. Demant, T., C. J. Packard, H. Demmelmair, P. Stewart, A. Bedynek, D. Bedford, D. Seidel, and J. Shepherd. 1996. Sensitive methods to study human apolipoprotein B metabolism using stable isotope-labeled amino acids. Am. J. Physiol. Endocrinol. Metab. 270: E1022–E1036.[Abstract/Free Full Text]

  29. Pietzsch, J., B. Wiedemann, U. Julius, S. Nitzsche, S. Gehrisch, S. Bergmann, W. Leonhardt, W. Jaross, and M. Hanefeld. 1996. Increased clearance of low density lipoprotein precursors in patients with heterozygous familial defective apolipoprotein B-100: a stable isotope approach. J. Lipid Res. 37: 2074–2087.[Abstract]

  30. Zheng, C., K. Ikewaki, B. W. Walsh, and F. M. Sacks. 2006. Metabolism of apoB lipoproteins of intestinal and hepatic origin during constant feeding of small amounts of fat. J. Lipid Res. 47: 1771–1779.[Abstract/Free Full Text]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
D600044-JLR200v1
48/9/2086    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Al-Shayji, I. A. R.
Right arrow Articles by Caslake, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Al-Shayji, I. A. R.
Right arrow Articles by Caslake, M. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Journal of Biological Chemistry 
 Molecular and Cellular Proteomics   ASBMB Today 
Advertisement
spacer
Advertisement
Advertisement